Across TCGA pan-cancer cohorts, NSFL1C Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NSFL1C data layer compared with 20 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NSFL1C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NSFL1C expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.
LUAD, BLCA, and LUSC are the cancer types where NSFL1C Mutation most reproducibly stratifies survival.